Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James K Earel

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cancer Research|January 7, 2006
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cellsJames K Earel, Rebecca L VanOosten, Thomas S Griffith
Apoptosis : an International Journal on Programmed Cell Death|December 30, 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activityRebecca L VanOosten, James K Earel, Thomas S Griffith
Journal of Oncology|June 24, 2009
[Not Available]Lyse A Norian, Tamara A Kucaba, James K Earel, et al.
Current Gene Therapy|March 12, 2009
TRAIL gene therapy: from preclinical development to clinical applicationThomas S Griffith, Brittany Stokes, Tamara A Kucaba, et al.
Blood|July 23, 2005
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2LTroy J Kemp, Aaron T Ludwig, James K Earel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cancer Research|January 7, 2006
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cellsJames K Earel, Rebecca L VanOosten, Thomas S Griffith
Apoptosis : an International Journal on Programmed Cell Death|December 30, 2006
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activityRebecca L VanOosten, James K Earel, Thomas S Griffith
Journal of Oncology|June 24, 2009
[Not Available]Lyse A Norian, Tamara A Kucaba, James K Earel, et al.
Current Gene Therapy|March 12, 2009
TRAIL gene therapy: from preclinical development to clinical applicationThomas S Griffith, Brittany Stokes, Tamara A Kucaba, et al.
Blood|July 23, 2005
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2LTroy J Kemp, Aaron T Ludwig, James K Earel, et al.
Pageof 1